UF research helps establish new FDA pathway for Parkinson’s diagnostics
On Friday, April 3, the U.S. Food and Drug Administration, or FDA, granted De Novo classification to Neuropacs™ Corp. for its diffusion MRI-based software, neuropacs™, which is designed to assist neurologists and neuroradiologists evaluate individuals with early-stage Parkinson’s disease. The approval was made possible by a National Institutes of Health-funded study…